The answer seems to be the latter. Times (UK) Report.
Maunjaro’s US-based manufacturer Elli Lily said that it was traveling hiking the UK list for medicine from 1 September to bring it to other countries …
Ellie Lily is increasing the amount that charges pharmacies. The rate for a medium -sized 5mg dose will be almost doubled, from £ 92 to £ 180. Maximum doses, 15mg, will increase from £ 122 to £ 330.
Will all Britain be affected? It seems that the answer is ‘no’. The NHS made a deal with Lily to provide more to Maunzaro, so it seems that prices would only be affected by the UK privately insured. How does Ellie Lily justify the increased price?
Elli Lily said: “After a review, Lily will increase the list of UK for Moonzaro from September 1 to address pricing discrepancies compared to other developed countries in Europe. In parallel, we have reached an agreement to reach an agreement with NHS, while Lily does not determine the prices that are working with private health providers, we are working with the patient.”
Lily said that she initially launched Maunzaro in the UK at a much below the European average “at a price” price to prevent delay in availability, but now it would have to change “to ensure” proper global contribution to the cost of innovation “.
This result can be stunning for many people, but economists have long understood that external reference pricing pricing not only in high price/high income countries, but it delays prices and/or drug launch in low price/low -income countries (Maini and Pammolli 2023; Holtorf et al. 2019; Inkz et al. 2022;
